Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.33B 2.92B 2.7B 2.49B 4.73B 319B 4.82B 32.44B 12.6B 156B 12.51B 12.24B 542B P/E 2026 *
-45.1x
P/E 2027 * -84.5x
Enterprise Value 3.22B 2.82B 2.6B 2.41B 4.56B 308B 4.65B 31.3B 12.16B 151B 12.07B 11.81B 523B EV / Sales 2026 *
11.2x
EV / Sales 2027 * 9.02x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day-3.77%
1 week-9.92%
Current month-6.06%
1 month+20.66%
3 months+35.78%
6 months+26.25%
Current year+24.08%
1 week 19.77
Extreme 19.7711
22.8
1 month 15.9
Extreme 15.9
22.8
Current year 12
Extreme 12
22.8
1 year 9.96
Extreme 9.9551
22.8
3 years 2.28
Extreme 2.28
22.8
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Head of Human Resources

120,564 0.0753%
06-30Sell

Executive/Senior Manager

-487 0.0003%
06-28Fiscal year

Executive/Senior Manager

361,358 0.2258%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-9.92%+71.64%+208.10% 3.33B
-0.56%-6.55%+110.42%+121.86% 4.48B
-0.95%-2.17%-29.90%-41.82% 1.96B
-1.03%+8.56%+143.50%-50.97% 1.94B
-2.63%-5.33%+43.84%+185.17% 1.46B
-2.45%-6.42%+108.51%-52.87% 873M
-3.58%-4.88%-10.03%+45.39% 881M
-1.61%+2.53%-36.86%-17.99% 487M
-8.72%-18.82%-5.99% - 488M
-6.81%-17.70% - - 182M
Average -3.27%-3.92%+43.90%+49.61% 1.61B
Weighted average by Cap. -2.19%-2.72%+68.09%+85.27%

Financials

2026 *2027 *
Net sales 287M 252M 233M 215M 407M 27.5B 415M 2.8B 1.09B 13.46B 1.08B 1.05B 46.72B 352M 309M 285M 263M 499M 33.72B 509M 3.43B 1.33B 16.5B 1.32B 1.29B 57.27B
Net income -71.97M -63.12M -58.28M -53.85M -102M -6.89B -104M -701M -272M -3.37B -270M -264M -11.71B -38.02M -33.35M -30.79M -28.45M -53.92M -3.64B -55M -370M -144M -1.78B -143M -140M -6.18B
Net Debt -117M -102M -94.55M -87.37M -166M -11.18B -169M -1.14B -442M -5.47B -438M -429M -18.99B -157M -137M -127M -117M -222M -14.99B -226M -1.52B -592M -7.34B -588M -575M -25.46B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-08 US$20.11 -3.41% 1,103,976
26-07-07 US$20.82 -3.16% 2,440,474
26-07-06 US$21.50 +1.46% 2,525,680
26-07-02 US$21.19 -5.27% 3,393,935
26-07-01 US$22.37 +4.29% 3,284,993
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
20.82USD
Average target price
20.29USD
Spread / Average Target
-2.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock